Utilities, Consumer...
Health Care: Drugs
Protalix BioTherapeutics Inc. (PLX: AMEX)
$6.50 -0.01 | -0.15%
02/09/12 - 04:01 PM ET
241.15K / 144.50K
Vol / Avg. Vol:6.60 / 6.51
Open / Prev. Close:6.37 - 6.64
Today's Range:4.06 - 9.90
52 Wk Range:32.05%
Performance YTD:TheStreet Rating:
Portfolios with PLX
- Portfolio NameUser Type
- UserSharebuilder
- UserSUPRATRADE HOT STOCKS (BUY ...
- Usergilver Portfolio 1
- UserTop Biotech Short Squeeze P...
- UserEdwin Lee Portfolio 1
- Usermokey Portfolio 1
- Userocino Portfolio 1
- Userthaiboxatl Portfolio 1
- Userrecentoutperform070824
- UserSUPRATRADE "BUY IT IMM...
Latest PLX Headlines from TheStreet
- Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX) 12.06.11 | 08:12 am
- Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX) 09.12.11 | 09:09 am
- Protalix BioTherapeutics Inc. Stock Downgraded (PLX) 08.31.11 | 07:08 am
- Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX) 08.18.11 | 10:08 am
- Protalix BioTherapeutics Inc. Stock Upgraded (PLX) 07.15.11 | 07:07 am
- 5 Stocks to Watch: Pandora, DST Systems 06.15.11 | 07:06 am
- Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX) 02.25.11 | 09:02 am
- Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX) 02.24.11 | 04:02 pm
- Biotech Stock Mailbag: Protalix BioTherapeutics 02.11.11 | 07:02 am
- Biotech Calendar: Key Dates for February 01.31.11 | 09:01 am
Press Releases for PLX
- FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012 - PR Newswire 12.06.11 | 07:12 am
- Protalix Announces Successful European GMP Audit - PR Newswire 12.01.11 | 02:12 am
- Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease - PR Newswire 11.10.11 | 01:11 am
- Protalix BioTherapeutics To Present At Four Upcoming Conferences - PR Newswire 10.26.11 | 07:10 am
- Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference - PR Newswire 09.21.11 | 07:09 am
- Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference - PR Newswire 09.13.11 | 08:09 am
- Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology - PR Newswire 09.08.11 | 08:09 am
- Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date - PR Newswire 08.17.11 | 07:08 am
- Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial - PR Newswire 08.01.11 | 08:08 am
- Protalix Announces Successful GMP Manufacturing Audit By Brazil's National Health Surveillance Agency - PR Newswire 06.15.11 | 07:06 am
Partner Headlines for PLX
- Company News for December 7, 2011 - Corporate Summary - Zacks 12.07.11 | 09:12 am
- Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point - Seeking Alpha 12.07.11 | 09:12 am
- Morning Market Losers - Benzinga 12.06.11 | 09:12 am
- 14 Small Caps With 2 or More Analyst Downgrades in March - Seeking Alpha 04.04.11 | 09:04 am
- What's Next for Protalix BioTherapeutics Shares Fall After FDA CRL? - Seeking Alpha 02.27.11 | 09:02 am
- UPDATE 3-U.S. seeks more data on Protalix drug; shares fall - Reuters 02.25.11 | 04:02 pm
- Protalix BioTherapeutics Trading Significantly Lower Today (PLX) - Benzinga 02.25.11 | 09:02 am
- iBio Overvalued - Seeking Alpha 02.09.11 | 08:02 am
- iBio: A True Paradigm Shift - Seeking Alpha 01.24.11 | 09:01 am
- Contrarian Ideas: 20 Healthcare Stocks With Low Put/Call Ratios - Seeking Alpha 01.18.11 | 07:01 am
